The first trials in the Xarelto Multidistrict Litigation (MDL) are scheduled to commence in August of 2016.
These trials will be used to test the arguments of both sides and could be crucial in moving the overall litigation forward.
About The Xarelto MDL
Xarelto is a popular blood thinner drug which is prescribed to treat various medical conditions including deep vein thrombosis and pulmonary embolism. It is also used to prevent blood clots in patients undergoing knee or hip replacement surgery.
The blockbuster drug has been prescribed more than 11 million times in the US since its initial FDA approval in 2011. However, Xarelto has become highly controversial after a number recent of studies linked the drug to dangerous side effects including severe internal bleeding.
Individuals and families from across the country are now filing lawsuits in relation to the allegedly dangerous side effects of Xarelto, claiming that companies involved in manufacturing and selling the drug acted negligently.
In October 2014, dozens of existing Xarelto lawsuits were consolidated into a Multidistrict Litigation in the US District Court for the Eastern District of Louisiana. The number of complaints involved in the MDL has since grown to more than 500 cases.
In a recent status meeting, the Judge presiding over the Xarelto MDL announced the dates of the first three bellwether trials. According to minute entries from the status meeting, the first trial will begin on August 1st, 2016 and will be followed by two more trials beginning on August 22nd and September 17th.
It was also noted that the first two trials will be held in the Eastern District of Louisiana, while the third trial will be held in the Southern District of Texas.
Xarelto lawyer Marc Goldich commented on the importance of the first trials saying, “The outcomes of the bellwether trials will help parties on both sides of this litigation in making decisions going forward and should help to speed up future litigation.”
Goldich is a sponsor of Sheller.com which provides helpful information about Xarelto litigation and access to legal representation for those who may have been harmed by Xarelto’s side effects.
For more information about this press release please contact Marc Goldich.